emergency treatment News
-
Showcase
Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...
-
Showcase
ARAI-2PAM Barda Procurement Award
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...
-
TargetSolutions’ EMS Continuing Education Course Examines Emergency Care for Allergies and Anaphylaxis
TargetSolutions’ EMS Allergies and Anaphylaxis Basic training course covers the topics of allergy-related incidents and the appropriate care needed in such situations. Allergic reactions can develop as simple irritations, but quickly mobilize into life-threatening emergencies. EMS responders are tasked with determining the severity of the condition as emergency medical care and rapid ...
-
Cellvie CEO Dr. Alexander Schueller was Awarded the Prestigious De Vigier Award
The W.A. de Vigier Foundation promotes and supports innovative entrepreneurial spirit in Switzerland. Since 1987, the goal of the foundation has been to invigorate emerging companies, providing support to young entrepreneurs, who stand out in the country's innovation-rich startup environment. Today, the De Vigier Award is one of the most respected prizes for young entrepreneurs in Switzerland, ...
By cellvie Inc.
-
Notal Vision raises up to $60 million to support development of its Home OCT technology and commercial growth of its ForeseeHome AMD Monitoring Program
Manassas, VA (June 1, 2021) - Notal Vision, Inc., a privately held ophthalmic home monitoring services provider focused on early disease detection and treatment monitoring is pleased to announce the closing of a Series D financing co-led by Soleus Capital and the company's majority shareholder Ganot Capital. Existing shareholders Elron and Evergreen contributed significantly to the round. The ...
-
CELLVIE wins the prestigious MedTech Innovator Value Award
MedTech Innovator is the leading program for medical devices, digital health and diagnostic companies and is the largest accelerator for life science companies globally. Every year, start-ups from all over the world are invited to present their solution and vision for a chance to be selected to join the MedTech Innovator Accelerator. The program culminates in a competition for a grand prize of ...
By cellvie Inc.
-
Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced the results from two clinical studies using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual MDS patients were featured in two poster presentations at the 63rd American Society of ...
-
LayerBio to Present Preclinical Results for Extended Release Glaucoma Formulation at ARVO
LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio's proprietary PolyNet delivery technology. LayerBio will present preclinical study results at the Association for Research in ...
-
TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021. The session, “New Era in Biologically-Targeted ...
-
RevMedx announces adoption of XSTAT gunshot wound treatment by emergency responders in Highland Park, Texas
RevMedx, Inc. announced today that the Highland Park Department of Public Safety (Highland Park, TX) is fielding XSTAT as a new treatment option in their medical and trauma kits. Located three miles north of Dallas, Highland Park Department of Public Safety works closely with other Dallas Metro services including Dallas Fire and Rescue and University Park Fire Department on Automatic Assistance ...
By RevMedx
-
Aikening Launch in Azerbaijan
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have failed initial treatment. The approval of ...
-
Corindus Completes First-Ever, Transcontinental Simulated Telerobotic Percutaneous Coronary Intervention Procedures Over 5G, Fiber, and Public Internet Networks
Corindus, a Siemens Healthineers company and a leading developer of precision vascular robotics, announced today it has completed the first multi-city, transcontinental percutaneous coronary intervention (PCI) simulations in the United States over three network connection types – 5G wireless, dedicated fiber, and commercial public internet networks. Interventional cardiologist Ryan Madder, ...
-
Endomedix Joins US Army Medical Research Groups in CRADA for Ocular Projectile Battlefield Trauma Project
Endomedix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement or CRADA with the US. Army Institute of Surgical Research (USAISR) and the U.S. Army Medical Materiel Development Activity (USAMMDA). The CRADA will address a specific topic, “Ocular Projectile Battlefield Trauma Project”, an unsolved emergency medical treatment problem for ...
-
AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema)
B244 reduced patients’ WI-NRS score by an average of 34.3% and achieved clinically meaningful 4-point itch response Lesional severity (appearance) improved for IGA and EASI Results were achieved in 4 weeks Safe and well tolerated with no SAEs and no single adverse event occurred in greater than 1% of the active group. AOBiome Therapeutics, a clinical stage biotechnology company ...
-
The Fab’entech biopharmaceutical company Fab’entech is launching the production of its treatment against Ebola.
Recognised for its production capacities, its short development lead times and the quality of its products, Fab’entech has accelerated its project to develop a treatment against Ebola, in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA). These highly-purified antibodies for use in humans aim to specifically and immediately ...
By Fab’entech
-
Aktiv Pharma Group Awarded a $24.5M US Government Project
[BROOMFIELD, MARCH 23, 2020] Aktiv Pharma Group has been awarded a $24.5 million US government project to develop an autoinjector treatment for exposure to nerve agents. The award is an Other Transaction (OT) prototype project by the Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEOCBRND). Under the 5-year, OT agreement, ...
-
Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of withdrawal or psychotomimetic effects associated with NMDAR blocking Relmada Therapeutics, Inc. (NASDAQ: ...
-
Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001
The Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics ...
-
GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the completion of its Piedmont ...
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you